Amicus Therapeutics Growth, Revenue, Number of Employees and Funding

Overview

Location:
Cranbury, NJ USA
Total Funding:$294.6M
Industry:Biotech
Founded:2002
Lead Investor(s):BofA Merrill Lynch
Press

Industry Ranking

State Ranking

Growjo 10k Ranking

Revenue & Financials

  • Amicus Therapeutics's revenue is currently $91.2M per year.
  • Amicus Therapeutics received $300.0M in venture funding in February 2018.
  • Amicus Therapeutics's revenue per employee is $171191
  • Amicus Therapeutics's total funding is $294.6M.

Employee Data

  • Amicus Therapeutics has 533 Employees.
  • Amicus Therapeutics grew their employee count by 22% last year.
  • Amicus Therapeutics currently has 66 job openings.

What Is Amicus Therapeutics?

Amicus Therapeutics is a global, patient-centric biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare metabolic diseases. We have a unique set of platform technologies and medicines in development for patients living with the Lysosomal Storage Disorders Fabry disease and Pompe disease and we are committed to advancing and expanding a robust pipeline of cutting-edge, first- or best-in-class medicines for these and other rare diseases. The needs of patients in the rare disease community are at the center of our inventive science, our commercial organization, and our clinical programs. Our goal throughout all levels of the organization is to make a meaningful difference in the lives of these patients and their caregivers. Several opportunities are available to join our team as we build a leading global biotechnology company focused on rare metabolic diseases. Our Amicus footprint spans 27 countries including our global headquarters in Cranbury, NJ and international headquarters in Gerrards Cross UK. Additional international office locations include Canada, Germany, Italy, The Netherlands, Spain, France, and Japan. More information about Amicus and our career opportunities can be found at www.amicusrx.com.

keywords:Biotechnology,Healthcare,Pharmaceuticals

533

Number of Employees

$91.2M

Revenue (est)

66

Current Jobs

22%

Employee Growth %

$294.6M

Total Funding

N/A

Valuation

N/A

Accelerator

B2B

Type

Similar Companies

NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
GENEWIZ
$75.8M5196%
Hitachi Chemica...
$29.9M22919%
GENEWIZ
$75.8M5196%
Hitachi Chemica...
$29.9M22919%
Canfield Scient...
$29.3M2048%
Thomas Scientif...
$21.5M16720%
Canfield Scient...
$29.3M2048%
Thomas Scientif...
$21.5M16720%
L Oreal USA
N/A5227%
L Oreal USA
N/A5227%

Amicus Therapeutics News

20-Mar-19 - How Excited Should You Be About Amicus Therapeutics, Inc. (FOLD

Looking at top Wall Street opinions, Amicus Therapeutics, Inc. (NASDAQ: FOLD) has recently made its way into the research list of Cantor

18-Mar-19 - Analysts Have Mixed Ratings On Amicus Therapeutics, Inc. (FOLD

The shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) has been pegged with a rating of Overweight by Cantor Fitzgerald in its latest

20-Mar-19 - Analyst Community Hate Or Love Amicus Therapeutics, Inc. (FOLD

Amicus Therapeutics, Inc. (NASDAQ:FOLD) recently ticked higher on strong volume. About 6006144 contracts were traded on 15-Mar-19

Amicus Therapeutics Funding

DateAmountRoundLead InvestorsReference
2003-10-01$1.0MPrivate OfferingArticle
2004-05-13$31.0MBCanaan PartnersArticle
2005-09-09$55.0MCQuaker BioVenturesArticle
2006-05-19$86.2MUndisclosedMorgan Stanley, Goldman Sachs and CoArticle
2006-09-15$60.0MDNew Enterprise AssociatesArticle
2006-09-28$60.0MUndisclosedArticle
2007-04-03$86.2MUndisclosedArticle
2007-06-04$60.0MUndisclosedMorgan Stanley and Co Incorpor, Merrill Lynch and CoArticle
2010-02-26$18.5MUndisclosedLeerink Swann LLCArticle
2012-03-05$54.0MUndisclosedLeerink Swann LLC , Cowen and Company LLCArticle
2013-12-05$15.0MUndisclosedArticle
2014-01-02$25.0MUndisclosedMidCap Financial, LLCArticle
2014-11-21$90.0MUndisclosedMultipleArticle
2014-11-25$103.5MUndisclosedJ.P. Morgan Securities LLCArticle
2015-06-15$258.8MUndisclosedJ.P. Morgan Securities LLCArticle
2017-07-14$258.8MUndisclosedJ.P. Morgan Securities LLCArticle
2018-02-19$300.0MUndisclosedBofA Merrill LynchArticle

Amicus Therapeutics Executive Hires

DateNameTitleReference
2005-01-25John F. CrowleyChairman / CEOArticle
2006-01-09David J. LockhartChf Scientific OffArticle
2006-04-03Donald J. HaydenChairmanArticle
2006-10-03James E. DentzerCFOArticle
2007-03-06John F. CrowleyPresident/CEOArticle
2010-02-08John CrowleyCEO/ChairmanArticle
2011-04-19John F. CrowleyChairmanArticle
2012-01-24Bradley L. CampbellChief Business OfficerArticle
2012-04-17William D. BairdCFOArticle
2015-04-28David AllsopSVP InternationalArticle
2016-07-13Andrew MulbergVP Regulatory StrategyArticle
2017-10-09Michael DiemSVP Business Corporate DevelopmentArticle

Amicus Therapeutics New Location/Offices

DateLocationReference
2008-09-16San Diego, CAArticle

Amicus Therapeutics Acquisitions

DateCompany NameAmountNotesReference
2013-11-21Callidus Biopharma, Inc.Cash Deal - Not CompleteArticle

Amicus Therapeutics Hiring Plans

DateNumber of EmployeesLocationReference
2019-02-27200PhiladelphiaArticle

Amicus Therapeutics Staff Cuts

DateNumber of EmployeesLocationReference
2013-11-2291 Employees or 14% WorkforceArticle